HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • FDA
  • EU Medical Device Regulation
  • Robotics
  • AI
  • Interviews

Business
  • Deals
  • Financing
  • Earnings
  • Startups
  • R&D
Policy & Regulation
  • Approvals
  • Recalls
  • Legislation
  • Compliance
  • IP & Litigation

Commercial Trackers
  • M&A Deals
  • Financing Deals
  • Executive Moves
  • Company Rankings
Regulatory Trackers
  • US Original PMAs
  • US PMA Supplements
  • US 510(k) Clearances
  • US De Novo Classifications
  • Non-US Approvals
  • US FDA Warning letters
  • US Breakthrough Devices
  • Global Guidance Tracker
Podcasts

Conference Coverage

Partner Insights

Medtech Insight Perspectives

Uncovering medtech commercial, market access and development trends.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
MedTech Insight logo
  1. Home
  2. >>Medtech Insight
  3. >>ESG

ESG

Diversity & Inclusion
  • FDA Looks To Achieve Greater Health Equity For Medical Device Access

    FDA Looks To Achieve Greater Health Equity For Medical Device Access

    Aug 07 2024 
    • By Brian Bossetta

    The US FDA has published a discussion paper as part of an effort to ensure all patients have timely access to safe and effective medical devices. The agency says the paper fits into a larger strategy of promoting health equity and is seeking public comment on the initiative.

  • Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’

    Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’

    Aug 01 2024 
    • By Ashley Yeo

    The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.

  • FDA's LDT Overhaul Should Go Back To Congress, Appropriations Report Says

    FDA's LDT Overhaul Should Go Back To Congress, Appropriations Report Says

    Jul 10 2024 
    • By Sarah Karlin-Smith and Elizabeth Orr

    A fiscal 2025 report from the US House Appropriations Committee instructs the FDA to halt implementation of its overhaul of LDT regulation. Members also showed concern about overseas device manufacturing and the availability of over-the-counter diagnostics. 

  • EU Guidelines On Justifying Phthalates In Medical Devices Applicable To Growing List Of Regulated Substances

    EU Guidelines On Justifying Phthalates In Medical Devices Applicable To Growing List Of Regulated Substances

    Jul 08 2024 
    • By Lauren Nardella

    The European Commission’s Scientific Committee on Health, Environmental and Emerging Risks makes minor changes to its phthalates benefit-risk guidelines based on stakeholder feedback. The guidelines could be increasingly relevant given their applicability to other carcinogenic, mutagenic or reprotoxic (CMR) and endocrine-disrupting (ED) substances, lists that are bound to go on growing as the EU implements its Chemicals Strategy for Sustainability under the Green Deal.


  • EU’s Historic PFAS Restriction Looms Over Medical Devices Sector

    EU’s Historic PFAS Restriction Looms Over Medical Devices Sector

    Jul 03 2024 
    • By Ryan Nelson

    The European Chemicals Agency’s committees for Risk Assessment (RAC) and Socio-Economic Analysis (SEAC) are evaluating sector by sector the proposed REACH restriction on PFAS and more than 5,600 public comments, reaching provisional conclusions on cosmetics at their June meetings. A date has not been set to consider PFAS uses in medical devices, which are numerous, essential, and in many cases devoid of alternatives, industry says.

  • Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

    Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

    Jun 27 2024 
    • By Sue Sutter and Ryan Nelson

    In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

  • Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

    Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

    Jun 26 2024 
    • By Sarah Karlin-Smith

    New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline. 

  • Physician And myTomorrows CEO Discusses FDA’s New Program To Advance Clinical Trial Diversity

    Physician And myTomorrows CEO Discusses FDA’s New Program To Advance Clinical Trial Diversity

    Jun 10 2024 
    • By Brian Bossetta

    The US FDA recently announced a new initiative aimed at improving access to cancer trials among traditionally underserved populations. myTomorrows CEO Michel van Harten talked to Medtech Insight about how the agency’s plan might reshape the landscape of clinical trials going forward.


  • European IVD Industry On Rocky Road; Veer Toward 'Pockets of Growth'

    European IVD Industry On Rocky Road; Veer Toward 'Pockets of Growth'

    Jun 06 2024 
    • By Natasha Barrow

    Despite challenges and projected European decline, the in vitro diagnostics market has enticing "pockets for growth" post-pandemic, industry leaders revealed at the MedTech Forum conference. Key drivers include healthcare decentralization and consumer pull for control over health. Opportunities exist in neurology, oncology, and direct-to-consumer testing.

  • Hospital At Home: Great On Paper, Not In Practice

    Hospital At Home: Great On Paper, Not In Practice

    May 13 2024 
    • By Hannah Daniel

    To avoid a wider health equity gap for home-use devices, companies should make social determinants of health a key consideration in device development, former nurse Amy Hester says.

  • Digital Health Review Founder Blair Hirst Focuses On Health Equity

    Digital Health Review Founder Blair Hirst Focuses On Health Equity

    May 10 2024 
    • By Elizabeth Orr

    As a biomedical engineer, Blair Hirst saw how health technology could help patients – and how some communities were slowest to benefit. As founder of the Digital Health Review, she now works to improve equity in health care spaces.

  • ICER Debuts Clinical Trial Diversity Assessment Framework

    ICER Debuts Clinical Trial Diversity Assessment Framework

    May 03 2024 
    • By Sue Sutter

    The new tool provides a way of quantifying the degree of diversity by race/ethnicity, sex and age in clinical trials, but the results will not factor into the US health technology assessment body’s cost effectiveness determinations for new drugs.


  • Alarming Rise Of Diabetes in Several US States, Study Shows

    Alarming Rise Of Diabetes in Several US States, Study Shows

    Apr 22 2024 
    • By Brian Bossetta

    A study of diabetes rates across the US over four years reveals significant increases in the disease in many states. Tobias Oerum, diabetes advocate and cofounder of the company that conducted the study, discussed the data and some of the factors contributing to this troubling trend with Medtech Insight.

  • Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

    Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

    Apr 17 2024 
    • By Sue Sutter

    US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.

  • BD’s CTO Beth McCombs Discusses Key Initiatives –  AI/Gen AI; DE&I Strategy; Succession Planning

    BD’s CTO Beth McCombs Discusses Key Initiatives – AI/Gen AI; DE&I Strategy; Succession Planning

    Mar 20 2024 
    • By Marion Webb

    BD CTO Beth McCombs discusses her role in driving innovation, including the integration of AI and generative AI to create efficiencies, and passion for creating a culture of inclusion, diversity and equity.

  • Biden Signs Sweeping Executive Order To Advance Women’s Health

    Biden Signs Sweeping Executive Order To Advance Women’s Health

    Mar 19 2024 
    • By Brian Bossetta

    President Joe Biden signed an executive order the White House said represents the most comprehensive executive action to date on improving women’s health. The move follows the president’s call during his State of the Union for Congress to invest $12bn in women’s health research.


  • EPA Final Rule Limits Use Of Ethylene Oxide

    EPA Final Rule Limits Use Of Ethylene Oxide

    Mar 14 2024 
    • By Elizabeth Orr

    The rule, which requires most device sterilization plants to track and report their EtO emissions, will go into effect in two years for the largest plants and three years for the smallest.

  • As A Young Woman Marissa Fayer ‘Fell’ Into Medtech. Now, As An Industry Leader, She’s Focused On Leveling The Field

    As A Young Woman Marissa Fayer ‘Fell’ Into Medtech. Now, As An Industry Leader, She’s Focused On Leveling The Field

    Mar 14 2024 
    • By Brian Bossetta

    Marissa Fayer is dedicated to advancing women’s health. The founder and CEO of HERhealthEQ, a global nonprofit focused on women’s health equity in emerging and developing countries, Fayer is also the CEO of DeepLook Medical. As part of our focus on women’s health in honor of Women’s History Month, Fayer spoke to Medtech Insight about the importance of having more women in all sectors of medtech, both for the benefit of industry as well as women patients.

  • Healthtech Responds To Providers’ Productivity, Workflow And Sustainability Concerns

    Healthtech Responds To Providers’ Productivity, Workflow And Sustainability Concerns

    Mar 13 2024 
    • By Ashley Yeo

    Healthtech innovators are being asked by users and clinicians how technology solutions can increase health system efficiency and respond to concerns over staff shortages. Royal Philips’ Bert van Meurs fielded these questions at ECR 2024.

  • Unfair Bias In Device Design: UK MHRA And Government Promise Action

    Unfair Bias In Device Design: UK MHRA And Government Promise Action

    Mar 13 2024 
    • By Ashley Yeo

    A 15-month UK independent review of ethnic and other biases in device design has called for treatment inequity to be addressed at the highest levels of government, more resources for the MHRA and equity assessments to be included in approvals and post market surveillance.

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • Medtech Top 100 Ranking
  • Data Trackers
  • FDA Warning Letters
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window